Journal of Molecular Medicine

, 89:1137

Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo

Authors

  • Zuzana Zachar
    • Department of Biochemistry and Cell BiologyStony Brook University
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
  • James Marecek
    • Department of ChemistryStony Brook University
  • Claudia Maturo
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
  • Sunita Gupta
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
  • Shawn D. Stuart
    • Department of Biochemistry and Cell BiologyStony Brook University
  • Katy Howell
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
  • Alexandra Schauble
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
  • Joanna Lem
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
  • Arin Piramzadian
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
  • Sameer Karnik
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
  • King Lee
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
  • Robert Rodriguez
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
  • Robert Shorr
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
    • Department of Biochemistry and Cell BiologyStony Brook University
    • Cornerstone Pharmaceuticals, Inc
    • Cornerstone Pharmaceuticals, Inc
Oiginal Article

DOI: 10.1007/s00109-011-0785-8

Cite this article as:
Zachar, Z., Marecek, J., Maturo, C. et al. J Mol Med (2011) 89: 1137. doi:10.1007/s00109-011-0785-8

Abstract

We report the analysis of CPI-613, the first member of a large set of analogs of lipoic acid (lipoate) we have investigated as potential anticancer agents. CPI-613 strongly disrupts mitochondrial metabolism, with selectivity for tumor cells in culture. This mitochondrial disruption includes activation of the well-characterized, lipoate-responsive regulatory phosphorylation of the E1α pyruvate dehydrogenase (PDH) subunit. This phosphorylation inactivates flux of glycolysis-derived carbon through this enzyme complex and implicates the PDH regulatory kinases (PDKs) as a possible drug target. Supporting this hypothesis, RNAi knockdown of the PDK protein levels substantially attenuates CPI-613 cancer cell killing. In both cell culture and in vivo tumor environments, the observed strong mitochondrial metabolic disruption is expected to significantly compromise cell survival. Consistent with this prediction, CPI-613 disruption of tumor mitochondrial metabolism is followed by efficient commitment to cell death by multiple, apparently redundant pathways, including apoptosis, in all tested cancer cell lines. Further, CPI-613 shows strong antitumor activity in vivo against human non-small cell lung and pancreatic cancers in xenograft models with low side-effect toxicity.

Keywords

Cancer Metabolism Mitochondria Lipoic acid PDH

Supplementary material

109_2011_785_MOESM1_ESM.pdf (186 kb)
ESM 1 (PDF 186 kb)
View video
ESM 2

(MOV 1641 kb)

View video
ESM 3

(MOV 2437 kb)

Copyright information

© Springer-Verlag 2011